Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $1.4MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Terrance Mcguire | Former Director | Aug 21 '26 | Proposed Sale | $37.61 | 10,200 | $383,671 | — | Aug 21 05:58 PM |
| Mcnamara Peter | Chief Scientific Officer | Aug 12 '26 | Option Exercise | $14.71 | 43 | $633 | 55,328 | Aug 14 07:25 PM |
| Mcnamara Peter | Chief Scientific Officer | Aug 12 '26 | Sale | $35.00 | 43 | $1,505 | 55,285 | Aug 14 07:25 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.